- The Wall Street Journal•2 days ago
U.S. regulators approved Amgen Inc.’s copy of the AbbVie Inc.’s anti-inflammatory treatment, Humira, which was the second-biggest selling drug in 2015.
- Associated Press•2 days ago
Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||174.55 x 100|
|Ask||175.10 x 100|
|Day's Range||174.61 - 176.85|
|52wk Range||130.09 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.89|
|Avg Vol (3m)||2,864,382|
|Dividend & Yield||4.00 (2.29%)|